COMPARTIVE ANIMAL CORE

比较动物核心

基本信息

批准号：
8516645
负责人：
Cheryl A London
金额：
$ 23.33万
依托单位：
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-06-05 至 2018-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8516645
关键词：
Adverse effects Adverse event Aftercare Anatomy Animal Model Animals Antineoplastic Agents Biological Markers Canis familiaris Childhood Clinical Clinical Trials Comparative Pathology Development Diagnosis Disease Drug Kinetics Evaluation Future Genetic Engineering Goals Housing Human In Vitro Individual Instruction London Malignant Neoplasms Maximum Tolerated Dose Medical Oncologist Modeling Mus Normal tissue morphology Oncology PTPRC gene Pathologist Pathology Patients Pharmacodynamics Phenotype Process Program Research Project Grants Progression-Free Survivals Research Personnel Resource Sharing Sampling Specimen Standardization Testing Therapeutic Tissue Banking Tissue Banks Tissue Sample Toxic effect Tumor Tissue Veterinary Medicine Veterinary Pathology Work Xenograft procedure anti-cancer therapeutic college comparative design drug candidate drug development drug discovery experience inhibitor/antagonist mouse model novel novel therapeutic intervention novel therapeutics osteosarcoma patient population research and development response sarcoma small molecule success therapeutic target tool tumor

项目摘要

The overall goal ofthe comparative animal core is to support the development and use ofthe animal models employed within this Program Project Grant. The guiding principals for the comparative animal core are efficient planning and utilization of tissue and tumor samples, standardization of processing and diagnoses, and continued development of the canine spontaneous tumor animal model. This Core is housed and coordinated in the Department of Veterinary Biosciences in the College of Veterinary Medicine at OSU and includes individuals with expertise in comparative pathology, tissue banking, and clinical trial development and execution. Dr. Cheryl London, the proposed Core Director, is a Board Certified Veterinary Medical Oncologist with extensive expertise in cancer drug development including validating novel targets, identifying appropriate small molecules for target inhibition, and testing these compounds in relevant canine cancers with the goal of providing critical information that can assist in the human drug development process. Drs. Krista La Perie and Brad Bolon, Co-Investigators, are Board Certified in Veterinary Anatomic Pathology and are experts in the field of comparative pathology, particularly with respect to mouse models of cancer and evaluation of novel therapeutics in these models. The primary objective of this Core is to assist investigators in determining both the toxicities and activity associated with novel therapeutic approaches in mouse models of sarcoma, to identify candidate drugs/treatments that are likely to have success in the clinical setting, and to evaluate these treatments in dogs with spontaneous sarcomas as a prelude to future human clinical trials. As such, the specific aims of this Core are to: 1) Provide a standardized histopathologic evaluation of sarcomas generated in mouse models of disease following treatment with various targeted therapeutics; 2) Identify adverse effects associated with treatment of mice with novel therapeutics. 3) Provide high quality normal and tumor tissue samples from dogs with spontaneous sarcomas; and 4) Assess the adverse event profile and biologic activity of a novel STATS inhibitor (LY5) in normal dogs and dogs with spontaneous osteosarcoma.

比较动物核心的总体目标是支持该计划项目赠款中采用的动物模型的开发和使用。比较动物核心的指导原理是组织和肿瘤样品的有效计划和利用，加工和诊断的标准化以及犬类自发肿瘤动物模型的持续发展。该核心在OSU兽医学院的兽医生物科学系中安置和协调，其中包括具有比较病理学，组织库以及临床试验开发和执行方面的专业知识的人。拟议中的核心主任谢丽尔·伦敦博士（Cheryl London）是一名经过认证的兽医医学肿瘤学家，在癌症药物开发方面拥有广泛的专业知识，包括验证新颖的目标，确定适当的小分子以靶向靶向抑制，并在相关的犬类癌症中测试这些化合物的目标，目的是提供可以帮助人类药物开发过程的关键信息。博士。 Krista la Perie和Brad Bolon（共同投资者）获得了兽医解剖病理学的董事会认证，并且是比较病理学领域的专家，尤其是在这些模型中的癌症小鼠模型和新型治疗学评估方面。该核心的主要目的是协助研究人员确定与肉瘤小鼠模型中新型治疗方法相关的毒性和活性，以鉴定可能在临床环境中成功的候选药物/治疗方法，并评估这些狗在狗中的主要治疗方法，并以肉瘤的自发性肉瘤为序曲，成为未来人类临床试验的序曲。因此，该核心的具体目的是：1）对用各种靶向疗法进行治疗后，对疾病小鼠模型中产生的肉瘤进行标准化的组织病理学评估； 2）确定与新型治疗剂治疗小鼠有关的不良影响。 3）提供具有自发肉瘤的狗的高质量正常和肿瘤组织样品； 4）评估具有自发性骨肉瘤的正常狗和狗中新型数据抑制剂（LY5）的不良事件概况和生物学活性。